Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03672175 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 581
- Enrollment target
NCT03672175 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 581 participants.
The verdict
NCT03672175, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 581 participants
- Enrollment target
Study Summary
This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult participants with major depressive disorder (MDD).
Interventions
- DRUG Placebo
- DRUG SAGE-217
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2018-11-19 |
| Est. Completion | 2020-03-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03672175
The ClinicalTrials.gov registry entry for NCT03672175 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 581 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03672175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03672175 about?
NCT03672175 is a clinical study titled "A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder". This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult participants with major depressive disorder (MDD).
What is the current status of trial NCT03672175?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 581 participants. The study started on 2018-11-19. Estimated completion is 2020-03-17.
What interventions are being tested in trial NCT03672175?
The interventions under investigation include: Placebo (DRUG), SAGE-217 (DRUG).
Who is sponsoring clinical trial NCT03672175?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.